Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Health Canada Approves Pembrolizumab/Surgery in Locally Advanced HNSCC

Summary by cancernetwork.com
Results from the phase 3 KEYNOTE-689 trial supported the agency’s approval of the pembrolizumab/surgery regimen in PD-L1–positive head and neck cancer.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

cancernetwork.comcancernetwork.com

Health Canada Approves Pembrolizumab/Surgery in Locally Advanced HNSCC

Results from the phase 3 KEYNOTE-689 trial supported the agency’s approval of the pembrolizumab/surgery regimen in PD-L1–positive head and neck cancer.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

cancernetwork.com broke the news in on Friday, August 15, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Health Canada icon

Health Canada

Canada icon

Canada

News
For You
SearchBlindspotLocal